Published: Sun, November 22, 2020
Medical | By

Oxford COVID Vaccine Safe, Effective, Especially in Older Adults

Oxford COVID Vaccine Safe, Effective, Especially in Older Adults

As of November 19, almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program.

"It was decided that the PMO-constituted Vaccine Task Force (VTF) will lay down the principles for emergency use authorisation while the National Expert Group On Vaccine Administration for COVID-19 (NEGVAC) should take the lead in setting the principles for advance market commitment, including vaccine pricing", a source said.

The annual production capacity for the COVID-19 vaccine will top 300 million doses, according to the company.

AstraZeneca and Oxford's vaccine works differently than the one created by Pfizer and Moderna. "People have had only mild symptoms", Liu Jingzhen, chairmen of Sinopharm, said in an interview, as reported by South China Morning Post. The data from an emergency program is inefficient and unable to determine a vaccine's effectiveness.

The issue of advance purchase commitment for vaccines, including pricing, was also discussed in a recent meeting attended by NITI Aayog Member (Health) Vinod Paul, Principal Scientific Advisor to the government K VijayRaghavan and Union Health Secretary Rajesh Bhushan.


Sinopharm's vaccines use an inactive form of the virus that is unable to reproduce in human cells to kick off immune responses in the body. The vaccine is now undergoing phase 3 clinical trials in Russian Federation and other countries. They have recruited approximately 60,000 people and blood samples of over 40,000 for their trials.

A leading Chinese vaccine maker said it has commenced phase-3 clinical trials for its COVID-19 vaccine and is planning to recruit 29,000 volunteers across the world.

American company Pfizer and German firm BioNTech announced on November 9 that their candidate, called BNT162b2, was more than 90 percent effective in preventing COVID-19.

Global trials are expected to begin in Uzbekistan late this month, followed by trials in Indonesia, Pakistan and Ecuador. "The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement.

Sinopharm didn't respond to Newsweek's request for comment in time for publication.

Like this: